Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zamicastat and Sildenafil Interaction Study
NCT04994860Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zamicastat in pulmonary arterial hypertension (PAH), sponsored by BIAL. Primary endpoints: Maximum observed concentration, Time to maximum concentration and 4 more. Started Mar 2018; status: completed.
02
Drugs
zamicastat
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04994860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04994860.